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Rationale: Dyspnea is the cardinal symptom in patients with any type of interstitial lung
disease (ILD); however, there are limited data on dyspnea among patients with connective
tissue disease-related ILD (i.e., CTD-ILD).
Objectives: To explore the utility of two dyspnea instruments (the University of California San
Diego Shortness of Breath Questionnaire [UCSD] and the Dyspnea-12 [D-12]) and use their
scores to examine the impact of dyspnea on the lives of patients with CTD-ILD.
Methods: Subjects were enrolled from the Autoimmune Lung Database (ALD) at National
Jewish Health. Chronbach’s alpha was used to assess the internal consistency reliability of
the two dyspnea questionnaires. We used the Multi-Dimensional Health Assessment Question-
naire [MDHAQ] as a measure of health status and examined associations between health status
and dyspnea by using Pearson productemoment correlation and linear regression.
Results: The internal consistency reliability of each of the two dyspnea questionnaires was
excellent (alphaZ 0.9 for each). There were significant correlations between either of the
two dyspnea measures and MDHAQ components. While controlling for ILD severity, dyspnea
as assessed by the UCSD, was a significant predictor of physical function (pZ 0.04),3 398 1621; fax: þ1 303 398 1040.
J.J. Swigris).
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Impact of dyspnea on patients with CTD-ILD 1351psychological well-being (pZ 0.005), and fatigue (pZ 0.02); dyspnea as assessed the D-12,
was a significant predictor of psychological well-being (pZ 0.01) and global status (pZ 0.03).
Conclusion: Dyspnea significantly affects day-to-day functioning and global well-being in
patients with CTD-ILD. The UCSD and D-12 yield meaningful information about these patients
that measures of pulmonary physiology cannot. Future studies should examine other perfor-
mance characteristics of these self-report measures in patients with CTD-ILD.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
The connective tissue diseases (CTD) have a number of
potential extra-articular manifestations, including lung
injury, and any of the lung’s compartmentsdairways, the
parenchyma or interstitium, vasculature, or pleuradmay be
independently or simultaneously affected. Interstitial lung
disease (ILD) is a common lung manifestation of CTDdit can
be a particularly prominent aspect of systemic sclerosis (SSc),
rheumatoid arthritis (RA), as well as the myositis spectrum of
diseasedand the resultant dyspnea can be extremely debili-
tating. When viewed histologically, ILD associated with CTD
(i.e., CTD-ILD) most often comprises a combination of lower
zone-predominant inflammation and scar (fibrosis). ILD is not
only commondseen in nearly 25% of patients with CTDdit
shortens survival with rates of only 60% at 10 years from
diagnosis.1,2
Several instruments have been designed to capture the
effect dyspnea has on patients with lung disease.3,4 Among
patients with idiopathic ILD (i.e., unrelated to CTD),
dyspnea induces physical inactivity and a number of
adverse downstream effects including deconditioning, loss
of independence, along with impaired emotional well-being
and overall quality of life (QOL).5e8 Although ILD is
a common manifestation of CTD and dyspnea, its principal
symptom, is burdensome and intrusive, questionnaires that
assess dyspnea are rarely used in clinical practice or as
research endpoints in studies enrolling subjects with CTD-
ILD.9,10 This may, in part, be due to limited information
regarding the presence and perception of dyspnea in these
patients, a knowledge gap that makes the question of what
the most appropriate tool to assess dyspnea in this pop-
ulation impossible to answer. To our knowledge only two
published studies that enrolled subjects with CTD-ILD have
systematically investigated dyspnea and its relationship
with other outcome measures.9,10 Both of them included
only subjects with SSc and suggested that dyspnea is
a driver of QOL and functional status.
The Health Assessment Questionnaire (HAQ) is a self-
report instrument originally developed to assess and
monitor health status and well-being in patients with RA.11
A multi-dimensional derivative of itdthe MDHAQ12,13dhas
been found to be useful to capture such information in
patients with various autoimmune and arthritic condi-
tions.14 Advantages of the MDHAQ include its applicability
across an array of conditions, its potential use as part of
routine clinical care, and its brief, yet comprehensive
composite summation index (termed “routine assessment
of patient index data” [RAPID]da score encompassing
function, pain, and global status). The RAPID was recently
validated for use in RA as a disease activity measure.15,16 A
different derivative of the HAQ (the HAQ DI), focused solelyon assessing one’s ability to perform activities of daily
living, has been administered to subjects with SSc
(including those with ILD10 or pulmonary arterial hyper-
tension17); however, the MDHAQ has yet to be administered
to any cohort of subjects with CTD-ILD. Many components
of the MDHAQ would seem to capture the scope of
impairment among patients with CTD-ILD (regardless of the
underlying CTD), and its broad applicability makes it an
attractive self-report instrument for research.
We conducted this study with two aims in mind: 1) to
further explore the effects of dyspnea in a cohort of subjects
with CTD-ILD; and 2) to examine the appropriateness,
internal consistency reliability, and utility of two dyspnea
instrumentsdthe University of California San Diego Short-
ness of Breath Questionnaire (UCSD)3 and the Dyspnea-12 (D-
12))18 in this patient group.Wehypothesized that each of the
two dyspnea questionnaires would have acceptable internal
consistency reliability. Further, because dyspnea affects
physical health and emotional well-being in patients with
CTD-ILD, we hypothesized that scores from the two dyspnea
questionnaires would correlate significantly with day-to-day
functioning and global well-being (as measured by various
components of the MDHAQ) and would yield meaningful
informationdbeyond what measures of pulmonary physi-
ology can providedabout CTD-ILD patients.
Methods
Subjects
The study sample was composed of consecutive subjects
with CTD-ILD enrolled in the Institutional Review Board
(IRB)-approved Autoimmune Lung Database (ALD) at
National Jewish Health during 2009. The CTD diagnoses
were made by a board-certified rheumatologist (AF) in
accordance with applicable American College of Rheuma-
tology criteria. The diagnosis of ILD was made by board-
certified pulmonologists with expertise in ILD and on the
basis of clinical, radiologic, and where available, patho-
logic criteria. Subjects enrolled in the ALD completed the
MDHAQ, UCSD, and D-12 at each visit prior to physician
evaluation. Pulmonary function tests were performed
according to ATS/ERS criteria.19e21 The protocol was
approved by the National Jewish Health IRB, and given the
retrospective design, granted exemption from full review.
Questionnaires
The MDHAQ
The MDHAQ is a modification of the original HAQ11 and is
a self-report instrument that includes items which assess
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includes visual analogue scales for pain and global status,
along with scale scores for fatigue, psychological distress,
morning stiffness, and change in status over the last week.
Thus, the MDHAQ yields seven scale scores (0e10, with 10
connoting greater impairment), five of which are the
physical function (FN), pain, psychological well-being,
fatigue, and patient-assessed global status. The FN, pain,
and patient-assessed global status scores are summed to
give the “RAPID3” subscale, scored 0e30. The MDHAQ takes
about 10 min for patients to complete and less than one
minute to analyze and score.13
The UCSD SOB Questionnaire
The UCSD is a 24-item instrument composed of 21 items
that ask respondents to rate the severity of dyspnea while
doing various activities; another item asks how limiting
dyspnea is; and the final two items focus on fear associated
with overexerting or with dyspnea itself.3 Simple summa-
tion scoring is used to yield scores from 0 to 120, with
higher scores corresponding to greater impairment.
The D-12
The D-12 is a unidimensional questionnaire with 12 items
derived from direct patient consultation and a systematic
search of relevant literature on the language that patients
use to describe dyspnea.18 Hierarchical modeling and
subsequent Rasch analysis was used to pare down the initial
pool of 81 items to 12. The D-12 provides a global score of
breathlessness severity that incorporates both “physical”
and “affective” aspects. The score is calculated using
simple summation of the responses for each item (0 “mild”
to 3 “severe”); thus, the total score ranges from 0 to 36,
with 36 representing maximal severity.
Statistical analysis
Baseline data are presented as percentages or means with
standard deviations as appropriate. We used Cronbach’s
alpha to estimate internal consistency reliability of the two
dyspnea questionnaires. Pearson productemoment corre-
lation was used to examine the relationship between
different outcomes. We used linear regression to further
examine relationships between pulmonary physiology,
MDHAQ component scores and dyspnea scores. Specifically,
we built two multivariable models for each of the FN,
Psychological distress, Fatigue, and Global MDHAQ compo-
nents (dependent variables in each model): one model had
as predictors UCSD scores and percentage of predicted
normal for race/age/gender/height forced vital capacity
(FVC%), and the other model had D-12 scores and FVC%.
This allowed us to examine the association between dysp-
nea and the four MDHAQ components while controlling for
ILD severity (with FVC%). We elected not to include both
FVC% and percent predicted diffusing capacity of the lung
for carbon monoxide (DLCO%) in each linear regression
model to avoid problems with collinearity, given the strong
correlation (rZ 0.8, p< 0.0001) between FVC% and DLCO%.
We considered a p-value< 0.05 as statistically significant.
All analyses were performed by using SAS, version 9.1.3
(SAS Institute; Cary, NC).Results
Forty-eight subjects were enrolled; their baseline data are
presented in Table 1. The internal consistency reliability of
each of the two dyspnea questionnaires was excellent
(alphaZ 0.9 for each). Table 2 displays correlations
between outcome measures. There were moderately strong
correlations between components of the MDHAQ. FVC%
correlated significantly with physical function (FN) but with
no other component of the MDHAQ; DLCO% did not corre-
late with any MDHAQ component. There was moderately
strong correlation between scores from the two dyspnea
instruments. There were significant correlations between
either of the two dyspnea measures and FN, psychological
well-being, fatigue, and patient-assessed global status.
Table 3 shows the results of the linear regression analyses.
While controlling for ILD severity, dyspnea as assessed by
the UCSD, was a significant predictor of physical function,
psychological well-being, and fatigue; as assessed by the D-
12, dyspnea was a significant predictor of psychological
well-being and patient-assessed global status.
Discussion
In this study, we administered self-report questionnaires to
subjects with CTD-ILD and found significant correlations
among their scores. To our surprise, in this cohort, lung
function (as measured by FVC% or DLCO%) was not signifi-
cantly associated with psychological well-being, fatigue, or
global status insofar as the MDHAQ assesses these domains;
however, as expected, dyspnea was associated with each of
these domains.
To our knowledge, this is the first study in which the
MDHAQ has been administered to patients with CTD-ILD;
thus, there are no published data available for direct
comparison. However, the MDHAQ component scores from
this cohort are similar to published scores from patients in
a general rheumatology clinic. In a study by Pincus and
Sokka,22 weighted average scores from the FN, patient-
assessed global status and Fatigue components of the
MDHAQ for 332 subjects with either RA, systemic lupus
erythematosus, or SSc were 2.8, 4.4, and 4.9 respectively,
whereas corresponding mean scores from our cohort were
2.3, 4.7, and 4.8. In our cohort, the RAPID scoreda
composite of the FN, PN, and Global compo-
nentsdsuggested moderate severity (high severity> 12).22
Investigators have used other HAQ derivatives in patients
with CTD. For example, Baron and colleagues9 observed
that dyspnea (as assessed by using items from the HAQ and
a modified version of the Pulmonary Functional Status and
Dyspnea Questionnaire23) was associated with HAQ scores,
as well as physical and mental health status (as measured
by the SF-36) in 151 subjects with SSc. It is unclear whether
those subjects had ILD; despite their mean FVC% of 90 (well
within normal range), we might presume some of them did.
The UCSD was originally developed for use in patients
with COPD.3 Our work represents the first systematic
evaluation of this tool for use in the assessment of activity-
related dyspnea in patients with CTD-ILD. Ferreira and
colleagues used the UCSD and other dyspnea questionnaires
to assess the effects of pulmonary rehabilitation in 99
Table 1 Baseline characteristics.
NZ 48
Age, yrs SD 52.8 19.7
Female:Male (%) 74:26
Race (%)
White 77
Black 4
Hispanic 17
Asian 0
Other 2
CTD (N)
Systemic sclerosis 20
Rheumatoid arthritis 8
Undifferentiated CTD 7
Poly-/dermatomyositis 7
Systemic lupus erythematosus 3
Primary Sjo¨gren’s syndrome 3
FVC% 72.1 21
FEV1% 73.7 21
DLCO% 51.6 21
MDHAQ components
FN 2.3 1.8
PS 2.7 2.2
Pain 4.2 3.2
Fatigue 4.8 3.2
Global 4.7 2.3
RAPID 11.2 6.6
Stiff in AM 32.5 38.8
Joints 9.8 9.2
Dyspnea questionnaires
D-12 12.3 10.2
UCSD 45.7 26.6
CTDZ connective tissue disease; FVC%Z percent of predicted
normal value for forced vital capacity; FEV1%Z percent of
predicted normal value for forced expiratory volume at
one second; DLCO%Z percent of predicted normal value
for diffusing capacity for carbon monoxide; MDHAQZ
Multi-dimensional Health Assessment Questionnaire; FNZ
physical function; PSZ psychological well-being component;
RAPIDZ scale composed of FN, Pain, and patient-assessed
global components; D-12Z Dyspnea-12; UCSDZ University of
San Diego Shortness of Breath Questionnaire.
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that study, only 29 subjects completed the UCSD, and their
mean score at baseline was 54.7. Mean FVC% and DLCO%
were not given for this subgroup, so their disease severity is
not known, and we are unable to make comparisons with
our results. In other studies, investigators have observed
that subjects with moderately severe (e.g., Global Initia-
tive for Chronic Obstructive Lung Disease [GOLD] stage II)
chronic obstructive pulmonary disease (COPD) have mean
UCSD scores in the mid-50s, and patients with GOLD stage III
COPD (e.g., percent predicted FEV1 of 25%) have mean
scores of 65.25 Although there is no staging system for ILD,
given their FVC% and DLCO%, subjects in our study would be
considered to have mild to perhaps moderate ILD, and their
mean UCSD score of 45.7 makes sense.We observed that dyspnea correlated with multiple
components of the MDHAQ, including day-to-day func-
tioning, psychological well-being, fatigue, and global
status. One reason for this is that both the MDHAQ and
dyspnea questionnaires are self-report, and scores from
self-report measures have an inherently greater likelihood
to be associated with each other than do outcomes with
differing characteristics (e.g., a score from a self-report
measure and a laboratory test value). Another reason is
that among patients with CTD-ILD, dyspnea is the
predominant respiratory symptomdit is bothersome and
intrusive; the significant correlations between MDHAQ
components and dyspnea scores bolsters the notion that
dyspnea is one driver of many aspects of CTD-ILD patients’
physical and mental health and global well-being.
Although focused on a similar symptom, the two dyspnea
questionnaires actually capture different information about
shortness of breath. The UCSD might best be regarded as
a dyspnea “status” instrument, assessing how short of breath
one becomes while performing various (predominantly day-
to-day) activities. The D-12 was developed based on the
responses from patients with a variety of cardiopulmonary
diseases, including ILD; thus, its items are deemed to be
relevant to theexperienceofdyspnea regardlessofunderlying
disease. In contrast to other dyspnea questionnaires
(including the UCSD), the D-12 is not activity dependent; it
measures the direct impact that dyspnea has on a patient.
Given this, it is not surprising thatD-12 scoresdidnot correlate
significantly with pulmonary physiology. Furthermore, this
well explains the results of the linear regression analyses: the
UCSD score was a significant predictor of day-to-day func-
tioning (theD-12was not), and theD-12 scorewas a significant
predictor of global sense of well-being (the UCSD was not).
These analyses also suggest that no matter the disease
severity (recall we controlled for disease severity in our
models), dyspnea significantly impacts health status domains
that are important to patients. The low R-square values
suggest thereare factorsbesidesdyspneaand ILD severity that
affect variability in the four health status domainsdwe
suspect these factors are related to the underlying CTD. For
example, fatigue is a well-known symptom of CTD, and our
data suggest components other than dyspnea and ILD severity
contribute to that symptom.
The primary limitation of the current study is the potential
for tertiary referral bias. This potential limitation is present in
any study generated in such amedical center.Wewould argue
that because of the complexity of the combination of diseases
in patients with CTD-ILD, along with the potentially toxic
medications used to treat them, a great number of patients
with CTD-ILD will be cared for in a referral center. Further,
based on their pulmonary physiology, our subjects hadmild to
at most moderate ILD; thus, they are likely representative of
CTD-ILD patients in the general population. The majority of
subjects had systemic sclerosis; unfortunately, we did not
have enough data to analyze subgroups based on type of CTD
separately. Hopefully, we can address this in future, larger,
prospective studies. Despite these potential limitations, we
believe this study has generated data useful for the study of
patients with CTD-ILD. Specifically, we observed that scores
from two dyspnea questionnairesdinstruments that measure
different but important aspects of shortness of breathdand
aCTD-specific questionnaire (theMDHAQ) providemeaningful
Table 2 Pearson productemoment correlation coefficients.
FNHAQ PSHAQ Pain Fatigue Global RAPID Stiff Joint FVC DLCO D-12 UCSD
FNHAQ e 0.6 0.45 0.5 0.62 0.74 0.24 0.53 0.37 0.29 0.36 0.58
<0.0001 0.002 0.0006 0.0006 <0.0001 0.3 0.0002 0.04 0.13 0.02 <0.0001
PSHAQ e e 0.44 0.62 0.58 0.62 0.53 0.62 0.04 0.06 0.48 0.53
0.002 <0.0001 <0.0001 <0.0001 0.01 <0.0001 0.8 0.8 0.001 0.0003
Pain e e e 0.51 0.68 0.88 0.46 0.67 0.03 0.1 0.22 0.14
0.0003 <0.0001 <0.0001 0.03 <0.0001 0.9 0.6 0.14 0.4
Fatigue e e e e 0.6 0.63 0.7 0.45 0.02 0.1 0.3 0.36
<0.0001 <0.0001 0.0004 0.002 0.9 0.6 0.04 0.02
Global e e e e e 0.91 0.5 0.6 0.08 0.1 0.43 0.34
<0.0001 0.02 <0.0001 0.7 0.6 0.004 0.03
RAPID e e e e e e 0.51 0.69 0.15 0.09 0.38 0.36
0.01 <0.0001 0.4 0.6 0.01 0.02
Stiff e e e e e e e 0.3 0.17 0.32 0.23 0.17
0.2 0.5 0.2 0.3 0.5
Joint e e e e e e e e 0.01 0.02 0.3 0.35
0.9 0.9 0.06 0.02
FVC e e e e e e e e e 0.8 0.26 0.6
<0.0001 0.16 0.0004
DLCO e e e e e e e e e e 0.34 0.53
0.08 0.004
D-12 e e e e e e e e e e e 0.4
0.004
UCSD e e e e e e e e e e e e
Values are correlation coefficient (top) and p-value (bottom); FNZ physical function component; PSZ psychological well-being
component; RAPIDZ scale composed of FN, Pain, and Global components; D-12Z Dyspnea-12; UCSDZ University of San Diego Short-
ness of Breath Questionnaire.
Table 3 Multivariable analyses examining relationships between MDHAQ components and either pulmonary physiology or
dyspnea. Each model includes one of the dyspnea measures (either D-12 or UCSD) and FVC%.
Outcome Model Predictors R-square of model Point estimate Standard error p-value
FN component Model #1 D-12 0.15 0.03 0.03 0.3
FVC% 0.02 0.01 0.1
Model #2 UCSD 0.23 0.02 0.01 0.04
FVC% 0.01 0.02 0.7
PS component Model #1 D-12 0.21 0.08 0.03 0.01
FVC% 0.02 0.01 0.3
Model #2 UCSD 0.24 0.04 0.01 0.005
FVC% 0.04 0.02 0.04
Global component Model #1 D-12 0.14 0.1 0.04 0.03
FVC% 0.02 0.02 0.5
Model #2 UCSD 0.08 0.04 0.02 0.1
FVC% 0.03 0.03 0.3
Fatigue component Model #1 D-12 0.11 0.1 0.05 0.06
FVC% 0.02 0.03 0.5
Model #2 UCSD 0.16 0.06 0.03 0.02
FVC% 0.05 0.03 0.1
FNZ physical function component; PSZ psychological well-being component; GlobalZ patient-assessed global component;
RAPIDZ scale composed of FN, Pain, and Global components; D-12Z Dyspnea-12; UCSDZ University of San Diego Shortness of Breath
Questionnaire.
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ology. Thus, this study begins the validation process for
MDHAQ, UCSD, and D-12 scores as measures of health status
and dyspnea in patients with CTD-ILD. Future studies should
assess the ability of scores from these instruments to
discriminate between subjects with differing severities of ILD
and with differing underlying CTD. It will also be important to
use health status and dyspnea questionnaires in longitudinal
fashion to help define CTD-ILD trajectory and finally to
establish theminimumscorechangeover timethat is clinically
meaningful (i.e., the MID) for each of these instruments.
In conclusion, the self-report measuresdMDHAQ, UCSD,
and D-12dare tools useful in the assessment of patients
with any of a wide spectrum of CTD-ILD. Most importantly,
these measures yield meaningful information that measures
of pulmonary physiology cannot. Not surprisingly, dyspnea
is strongly associated with day-to-day functioning and
global well-being in this patient population. Future studies
should examine other performance characteristics of these
self-report measures in patients with CTD-ILD.
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